| Results Support a Relationship Between a Lower NKCC and Greater CFS Severity |
CFS Case Definition |
Number of Patients and Controls Studied |
Comments |
Reference |
| Yes |
1988 CDC |
CFS: 16
Recovering from CFS: 7 Healthy: 12 |
NKCC of CFS pts was ↓68% compared to healthy control. In contrast, 7 patients either recovering or recovered from CFS did not exhibit a decrease in NKCC vs. the healthy controls. 51Cr-release assay, K562=target |
[28] |
| Yes |
1988 CDC |
CFS: 10
Fatigued,non-CFS: 24
Healthy: 21 (non-fatigued controls) |
2 E:T ratios
10:1 and 20:1,
51Cr-release assay, K562= target |
[26] |
| Yes |
1988 CDC |
Least severe CFS (n=10), more severe CFS (n=7),
most severe CFS (n=3)
Healthy: 50 |
Mean NKCC= 61 LU (Least severe);
18 LU (more severe);
8 LU (most severe), 51Cr-release assay, K562= target |
[27] |
| Yes |
1988 and 1994 CDC |
Isoprinosine treated CFS: 10 Placebo treated CFS: 6 |
Improvement in NKCC seen in 6 clinically improved CFS pts vs. 4 non-improved pts (p<0.03). 51Cr-release assay, K562= target |
[41] |
| Yes |
1994 CDC |
CFS: 41 female patients classified into 2 groups
Low NKCC, n=22
Normal NKCC, n=19 |
CFS cohort with low NKCC had less vigor, more daytime dysfunction, and more cognitive impairment compared to the CFS cohort with normal NKCC. 51Cr- release assay, K562= target |
[42] |
| Yes |
1994 CDC |
Severe CFS: 18
Moderate CFS: 23
Healthy: 22 |
3 E:T ratios
12.5:1, 25:1, 50:1 were studied using flow cytometry, K562=target |
[43] |
| LU: Lytic Units |
